Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Nanocrytals-Mediated Oral Drug Delivery: Enhanced Bioavailability of Amiodarone.

Tytuł:
Nanocrytals-Mediated Oral Drug Delivery: Enhanced Bioavailability of Amiodarone.
Autorzy:
Awan AM; Department of Pharmacy, Quaid-i-Azam University, Islamabad 45320, Pakistan.
Farid A; Gomal Center of Biochemistry and Biotechnology, Gomal University, Dera Ismail Khan 29050, Pakistan.
Shah SU; Skin/Regenerative Medicine and Drug Delivery Research, GCPS, Faculty of Pharmacy, Gomal University, Dera Ismail Khan 29050, Pakistan.
Khan D; Department of Pharmacy, Quaid-i-Azam University, Islamabad 45320, Pakistan.
Ur Rehman F; Department of Pharmacy, Quaid-i-Azam University, Islamabad 45320, Pakistan.
Dar MJ; Department of Pharmacy, Quaid-i-Azam University, Islamabad 45320, Pakistan.
Iftikhar T; Department of Pharmacy, Abdul Wali Khan University, Mardan 23200, Pakistan.
Ghazanfar S; Functional Genomics and Bioinformatics, National Agricultural Research Centre, Islamabad 45500, Pakistan.
Galanakis CM; Research & Innovation Department, Galanakis Laboratories, 73131 Chania, Greece.; Food Waste Recovery Group, ISEKI Food Association, 1190 Vienna, Austria.; Department of Biology, College of Science, Taif University, Taif 26571, Saudi Arabia.
Alamri AS; Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University, Taif 21944, Saudi Arabia.; Centre of Biomedical Sciences Research (CBSR), Deanship of Scientific Research, Taif University, Taif 21944, Saudi Arabia.
Asdaq SMB; Department of Pharmacy Practice, College of Pharmacy, AlMaarefa University, Dariyah, Riyadh 13713, Saudi Arabia.
Shah KU; Department of Pharmacy, Quaid-i-Azam University, Islamabad 45320, Pakistan.
Źródło:
Pharmaceutics [Pharmaceutics] 2022 Jun 18; Vol. 14 (6). Date of Electronic Publication: 2022 Jun 18.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Original Publication: Basel, Switzerland : MDPI
References:
Int J Pharm. 2021 Dec 15;610:121242. (PMID: 34737113)
Adv Drug Deliv Rev. 2007 Jul 30;59(7):631-44. (PMID: 17601629)
Int J Pharm. 2009 Jun 5;374(1-2):106-13. (PMID: 19446766)
Res Pharm Sci. 2015 Mar-Apr;10(2):95-108. (PMID: 26487886)
Drug Dev Ind Pharm. 2012 Oct;38(10):1230-9. (PMID: 22229827)
Int J Nanomedicine. 2015 Oct 12;10:6339-53. (PMID: 26491298)
Cardiovasc Drugs Ther. 2013 Apr;27(2):125-32. (PMID: 23344929)
Eur J Pharm Biopharm. 2006 Jan;62(1):3-16. (PMID: 16129588)
Int J Nanomedicine. 2016 May 27;11:2359-67. (PMID: 27313453)
Int J Pharm. 2017 Jan 10;516(1-2):372-379. (PMID: 27880871)
Chem Pharm Bull (Tokyo). 2015;63(4):295-9. (PMID: 25832024)
AAPS PharmSciTech. 2012 Mar;13(1):295-304. (PMID: 22246736)
Pharm Sci Technol Today. 2000 Apr;3(4):138-145. (PMID: 10754543)
Pharmaceutics. 2022 Mar 23;14(4):. (PMID: 35456525)
Langmuir. 2006 Jan 31;22(3):906-10. (PMID: 16430247)
J Control Release. 2010 Feb 15;141(3):300-2. (PMID: 19822177)
Contributed Indexing:
Keywords: amiodarone HCl; bioavailability enhancement; drug delivery; nanocrystals; pluronic F-127
Entry Date(s):
Date Created: 20220624 Latest Revision: 20230308
Update Code:
20240105
PubMed Central ID:
PMC9245605
DOI:
10.3390/pharmaceutics14061300
PMID:
35745871
Czasopismo naukowe
The aim of this study was to improve the saturation solubility, dissolution profile and oral bioavailability of amiodarone hydrochloride (AMH), a highly lipophilic drug. Stabilizer (Pluronic F-127)-coated AMH nanocrystals (AMH-NCs) were developed by a combination of antisolvent precipitation and homogenization techniques. The optimized formulation comprised pluronic F-127 and AMH at the concentration of 4% and 2% w/v, respectively. The particle size (PS), zeta potential (ZP) and polydispersity index (PDI) of the optimized formulation was found to be 221 ± 1.2 nm, 35.3 mV and 0.333, respectively. The optimized formulation exhibited a rough surface morphology with particles in colloidal dimensions and a significant reduction in crystallinity of the drug. AMH-NCs showed a marked increase in the saturation solubility as well as rapid dissolution rate when compared with the AMH and marketed product. The stability study displayed that the formulation was stable for 3 months, with no significant change in the PS, ZP and PDI. The in vivo pharmacokinetic study demonstrated the ability of AMH-NCs to significantly (p < 0.05) improve the oral bioavailability (2.1-fold) of AMH in comparison with AMH solution, indicating that the production of AMH-NCs using a combination of antisolvent precipitation and homogenization techniques could enhance the bioavailability of the drug.
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies